Dicerna Pharmaceuticals (DRNA) Position Maintained by Ecor1 Capital Llc; Sands Capital Management Raised Its Yandex N V (YNDX) Position

April 20, 2018 - By Peter Erickson

Yandex N.V. (NASDAQ:YNDX) Logo

Sands Capital Management Llc increased its stake in Yandex N V (YNDX) by 5.22% based on its latest 2017Q4 regulatory filing with the SEC. Sands Capital Management Llc bought 157,700 shares as the company’s stock rose 25.49% while stock markets declined. The institutional investor held 3.18 million shares of the programming company at the end of 2017Q4, valued at $104.16 million, up from 3.02M at the end of the previous reported quarter. Sands Capital Management Llc who had been investing in Yandex N V for a number of months, seems to be bullish on the $10.97B market cap company. The stock decreased 2.52% or $0.865 during the last trading session, reaching $33.525. About 2.94 million shares traded. Yandex N.V. (NASDAQ:YNDX) has risen 79.21% since April 20, 2017 and is uptrending. It has outperformed by 67.66% the S&P500.

Ecor1 Capital Llc increased its stake in Dicerna Pharmaceuticals Inc (DRNA) by 404.86% based on its latest 2017Q4 regulatory filing with the SEC. Ecor1 Capital Llc bought 3.88M shares as the company’s stock rose 19.47% while stock markets declined. The institutional investor held 4.84 million shares of the health care company at the end of 2017Q4, valued at $43.67M, up from 957,992 at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Dicerna Pharmaceuticals Inc for a number of months, seems to be bullish on the $694.71 million market cap company. The stock increased 31.70% or $3.23 during the last trading session, reaching $13.42. About 4.22 million shares traded or 844.00% up from the average. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 274.53% since April 20, 2017 and is uptrending. It has outperformed by 262.98% the S&P500.

Among 9 analysts covering Yandex N.V. (NASDAQ:YNDX), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Yandex N.V. had 22 analyst reports since July 31, 2015 according to SRatingsIntel. Deutsche Bank maintained Yandex N.V. (NASDAQ:YNDX) rating on Friday, July 31. Deutsche Bank has “Buy” rating and $20 target. The rating was maintained by Deutsche Bank on Tuesday, January 16 with “Buy”. The stock has “Buy” rating by Deutsche Bank on Wednesday, October 25. Citigroup downgraded the shares of YNDX in report on Friday, May 6 to “Neutral” rating. The firm has “Neutral” rating by Goldman Sachs given on Wednesday, September 16. The stock of Yandex N.V. (NASDAQ:YNDX) has “Overweight” rating given on Tuesday, November 17 by Morgan Stanley. The company was upgraded on Thursday, March 29 by Citigroup. The stock of Yandex N.V. (NASDAQ:YNDX) earned “Hold” rating by Zacks on Tuesday, August 4. The rating was initiated by HSBC on Monday, July 18 with “Buy”. As per Friday, September 11, the company rating was downgraded by Citigroup.

Sands Capital Management Llc, which manages about $42.07 billion and $32.98B US Long portfolio, decreased its stake in Alexion Pharmaceuticals Inc (NASDAQ:ALXN) by 222,852 shares to 4.55 million shares, valued at $544.51 million in 2017Q4, according to the filing. It also reduced its holding in Medidata Solutions Inc (NASDAQ:MDSO) by 63,630 shares in the quarter, leaving it with 3.55 million shares, and cut its stake in Regeneron Pharmaceuticals (NASDAQ:REGN).

Investors sentiment increased to 3 in 2017 Q4. Its up 2.21, from 0.79 in 2017Q3. It is positive, as 6 investors sold DRNA shares while 5 reduced holdings. 18 funds opened positions while 15 raised stakes. 29.10 million shares or 180.62% more from 10.37 million shares in 2017Q3 were reported. Panagora Asset Management holds 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 7,533 shares. Bankshares Of Ny Mellon Corporation holds 0% or 19,579 shares. Dimensional Fund Advsrs Limited Partnership, Texas-based fund reported 18,244 shares. Emerald Advisers Inc Pa owns 29,504 shares or 0.01% of their US portfolio. Cormorant Asset Ltd Liability Corporation has 3.66 million shares for 3.46% of their portfolio. California Public Employees Retirement Systems accumulated 0% or 41,000 shares. Retail Bank Of America De owns 35 shares. 194,198 are owned by Goldman Sachs Gp. 117,321 are held by Blackrock. Royal Financial Bank Of Canada has invested 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bnp Paribas Arbitrage holds 32 shares. First Manhattan holds 0.02% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 428,100 shares. Ecor1 Capital Limited Liability owns 4.84 million shares. State Street accumulated 0% or 10,321 shares. Emerald Mutual Fund Advisers Trust holds 0.2% or 570,861 shares.

Since December 18, 2017, it had 1 insider buy, and 1 sale for $1.98 million activity. Shares for $2.00 million were bought by Bain Capital Life Sciences Investors – LLC.

Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 25 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given on Friday, August 11 by H.C. Wainwright. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus on Thursday, June 30. The rating was maintained by Cowen & Co with “Buy” on Wednesday, August 16. As per Monday, February 5, the company rating was initiated by SunTrust. Cowen & Co initiated the shares of DRNA in report on Wednesday, April 11 with “Buy” rating. The firm has “Hold” rating by Chardan Capital Markets given on Friday, March 9. The rating was initiated by H.C. Wainwright on Monday, December 12 with “Buy”. The stock has “Buy” rating by Stifel Nicolaus on Wednesday, November 11. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Hold” rating given on Tuesday, March 27 by FBR Capital. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, November 2.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>